Since Ozempic’s 2017 approval, thousands of studies have explored its effects|C4U|CC BY-SA 2.0

Research suggests GLP-1 drugs like Ozempic and Wegovy may offer health benefits beyond curbing diabetes and weight loss, potentially helping with age-related Alzheimer’s, osteoarthritis and heart disease.

Since Ozempic’s 2017 approval, thousands of studies have explored these effects, according to the Wall Street Journal.

Researchers have found that GLP-1s may lower Alzheimer’s risk by 40%–70% in older diabetes patients. However, experts warn that more studies are needed, especially on healthy individuals. 

Though there are side effects to GLP-1s, which include nausea, constipation and muscle loss, telehealth companies focusing on longevity are promoting microdosing GLP-1s. However, manufacturers warn against this practice.

The obesity drug market is expected to hit $159 billion by 2030.